Jaguar Health R&D Spending Growth & History (JAGX)
Jaguar Health's r&d spending was $25.0M for fiscal 2025.
View full Jaguar Health company overviewJaguar Health annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.0M | $8.4M | +50.92% |
| 2024 | 2024-12-31 | $16.5M | −$2.1M | −11.05% |
| 2023 | 2023-12-31 | $18.6M | $949,000 | +5.38% |
| 2022 | 2022-12-31 | $17.6M | $2.6M | +17.03% |
| 2021 | 2021-12-31 | $15.1M | $8.7M | +135.13% |
| 2020 | 2020-12-31 | $6.4M | $593,000 | +10.19% |
| 2019 | 2019-12-31 | $5.8M | $665,252 | +12.91% |
| 2018 | 2018-12-31 | $5.2M | $885,293 | +20.74% |
| 2017 | 2017-12-31 | $4.3M | −$2.9M | −40.76% |
| 2016 | 2016-12-31 | $7.2M | $731,013 | +11.29% |
| 2015 | 2015-12-31 | $6.5M | $2.3M | +53.44% |
| 2014 | 2014-12-31 | $4.2M | — | — |
Jaguar Health quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | $71,000 | +2.17% |
| Q1 2026 | 2026-03-31 | $3.9M | $198,000 | +5.31% |
| Q4 2025 | 2025-12-31 | $14.3M | $9.8M | +215.68% |
| Q3 2025 | 2025-09-30 | $3.7M | −$385,000 | −9.52% |
| Q2 2025 | 2025-06-30 | $3.3M | −$388,000 | −10.62% |
| Q1 2025 | 2025-03-31 | $3.7M | −$582,000 | −13.50% |
| Q4 2024 | 2024-12-31 | $4.5M | $1.1M | +30.93% |
| Q3 2024 | 2024-09-30 | $4.0M | −$2.0M | −33.51% |
| Q2 2024 | 2024-06-30 | $3.7M | −$624,000 | −14.59% |
| Q1 2024 | 2024-03-31 | $4.3M | −$463,000 | −9.70% |
| Q4 2023 | 2023-12-31 | $3.5M | −$848,000 | −19.67% |
| Q3 2023 | 2023-09-30 | $6.1M | $141,000 | +2.37% |
| Q2 2023 | 2023-06-30 | $4.3M | $1.8M | +74.50% |
| Q1 2023 | 2023-03-31 | $4.8M | −$170,000 | −3.44% |
| Q4 2022 | 2022-12-31 | $4.3M | −$1.2M | −21.38% |
| Q3 2022 | 2022-09-30 | $5.9M | $2.6M | +79.35% |
| Q2 2022 | 2022-06-30 | $2.5M | −$1.4M | −36.67% |
| Q1 2022 | 2022-03-31 | $4.9M | $2.5M | +104.85% |
| Q4 2021 | 2021-12-31 | $5.5M | $3.6M | +187.97% |
| Q3 2021 | 2021-09-30 | $3.3M | $1.8M | +117.61% |
| Q2 2021 | 2021-06-30 | $3.9M | $2.5M | +175.44% |
| Q1 2021 | 2021-03-31 | $2.4M | $832,000 | +52.59% |
| Q4 2020 | 2020-12-31 | $1.9M | $510,000 | +36.59% |
| Q3 2020 | 2020-09-30 | $1.5M | $215,000 | +16.45% |
| Q2 2020 | 2020-06-30 | $1.4M | −$293,000 | −17.26% |
| Q1 2020 | 2020-03-31 | $1.6M | $161,000 | +11.33% |
| Q4 2019 | 2019-12-31 | $1.4M | $83,170 | +6.34% |
| Q3 2019 | 2019-09-30 | $1.3M | −$174,166 | −11.76% |
| Q2 2019 | 2019-06-30 | $1.7M | $93,114 | +5.80% |
| Q1 2019 | 2019-03-31 | $1.4M | $663,134 | +87.50% |
| Q4 2018 | 2018-12-31 | $1.3M | $75,226 | +6.09% |
| Q3 2018 | 2018-09-30 | $1.5M | $629,558 | +73.93% |
| Q2 2018 | 2018-06-30 | $1.6M | $678,095 | +73.17% |
| Q1 2018 | 2018-03-31 | $757,866 | −$497,586 | −39.63% |
| Q4 2017 | 2017-12-31 | $1.2M | −$298,744 | −19.47% |
| Q3 2017 | 2017-09-30 | $851,608 | −$1.1M | −56.71% |
| Q2 2017 | 2017-06-30 | $926,791 | −$1.0M | −52.56% |
| Q1 2017 | 2017-03-31 | $1.3M | −$496,289 | −28.33% |
| Q4 2016 | 2016-12-31 | $1.5M | −$527,341 | −25.58% |
| Q3 2016 | 2016-09-30 | $2.0M | $727,297 | +58.66% |
| Q2 2016 | 2016-06-30 | $2.0M | $202,359 | +11.55% |
| Q1 2016 | 2016-03-31 | $1.8M | $328,698 | +23.10% |
| Q4 2015 | 2015-12-31 | $2.1M | $1.1M | +118.32% |
| Q3 2015 | 2015-09-30 | $1.2M | $113,395 | +10.07% |
| Q2 2015 | 2015-06-30 | $1.8M | $1.1M | +153.38% |
| Q1 2015 | 2015-03-31 | $1.4M | −$35,332 | −2.42% |
| Q4 2014 | 2014-12-31 | $944,347 | — | — |
| Q3 2014 | 2014-09-30 | $1.1M | — | — |
| Q2 2014 | 2014-06-30 | $691,180 | — | — |
| Q1 2014 | 2014-03-31 | $1.5M | — | — |
Jaguar Health r&d spending trends
Over the last five fiscal years, Jaguar Health's r&d spending increased from $6.4M to $25.0M, a change of $18.6M. The latest reported quarter, Q2 2026, shows $3.3M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jaguar Health source filings ↗